CURRENT PERCEPTION OF UPCOMING COST-EFFECTIVENESS REQUIREMENTS IN JAPAN- A SURVEY ON THE PERSPECTIVE OF PHARMACEUTICAL INDUSTRY
Author(s)
Kim HR, Sugimoto T, Kamae I
The University of Tokyo, Graduate School of Public Policy, Tokyo, Japan
Presentation Documents
OBJECTIVES: In anticipation of official requirements of economic evidence by the Japanese government from April 2016, the present study aims to assess past experience and current capability of the industry to submit the economic evidence to the government, and to identify what the industry perceives for their capacity building. METHODS: A self-administered questionnaire was distributed to a person who was in charge of economic evidence or those most relevant (e.g., those in charge of market access), within every 72 member companies of Japanese Pharmaceutical Manufacturers Association, in March 2015. Semi-structured interviews were conducted with three HEOR experts of the pharamceutical industry to assess the consistency of the survey results. RESULTS: The interviewee’s responses were consistent with the survey results. CONCLUSIONS: Our survey observed that industry’s concerns regarding the upcoming policy are high and their preparedness is limited. For the industry to respond appropriately to the new policy, further improvement in transparency of requirements will be a key, in addition to capacity building in the industry
Conference/Value in Health Info
2015-11, ISPOR Europe 2015, Milan, Italy
Value in Health, Vol. 18, No. 7 (November 2015)
Code
PHP269
Topic
Health Technology Assessment
Topic Subcategory
Decision & Deliberative Processes
Disease
Multiple Diseases